Dopamine transporter mutants selectively enhance MPP+ transport

S. Kitayama, J. B. Wang, G. R. Uhl

Research output: Contribution to journalArticlepeer-review

Abstract

MPP+ (1-methyl-4-phenylpyridinium), a dopaminergic neurotoxin that provides the best available experimental model of Parkinson's disease, is selectively concentrated in dopamine neurons by the dopamine transporter (DAT). DAT also serves as a primary recognition site for cocaine. To help define selective molecular mechanisms by which MPP+ uptake occurs, we have tested dopamine transporters mutated in several residues for their abilities to accumulate dopamine and MPP+, and to bind a cocaine analog. Mutants in DAT 7th and 11th hydrophobic putative transmembrane domains increase MPP+ uptake velocity and affinity (1/K(D)), respectively. These mutations exert much more modest effects on dopamine uptake and have little impact on cocaine analog binding. These findings provide the first example of mutations that enhance transport and identify specific DAT amino acids selectively involved in neurotoxin uptake. They may also have implications for the feasibility of developing drugs that could specifically block accumulation of Parkinsonism- inducing neurotoxins.

Original languageEnglish (US)
Pages (from-to)58-62
Number of pages5
JournalSynapse
Volume15
Issue number1
StatePublished - 1993

ASJC Scopus subject areas

  • Physiology
  • Neuroscience(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'Dopamine transporter mutants selectively enhance MPP+ transport'. Together they form a unique fingerprint.

Cite this